Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 19NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Other 2Gastrointestinal 2Breast 2Thoracic 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Dermatologic 1

Conditions

Mouth Neoplasms 1Leukoplakia, Oral 1Hyperplasia 1Erythroplasia 1

Interventions

Cisplatin 38Radiotherapy 35Magnetic Resonance Spectroscopy 32Specimen Handling 22Cetuximab 18Fluorouracil 17Radiotherapy, Intensity-Modulated 16Platinum 161,2-diaminocyclohexaneplatinum II citrate 16Biopsy 15Paclitaxel 13Carboplatin 13Nivolumab 11Docetaxel 10pembrolizumab 8Radiation 8Fluorodeoxyglucose F18 8Erlotinib Hydrochloride 8Bortezomib 8Bevacizumab 8Gemcitabine 7Sorafenib 6Immunoglobulin G 6Disulfides 6aldesleukin 5Hydroxyurea 5Gefitinib 5Chemotherapy, Adjuvant 5(225)Ac-DOTA-c(RGDyK) 5cabozantinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Metformin × Head & Neck × Clear all
NCT02581137 2026-04-13

Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion

National Cancer Institute (NCI)

Phase 2 Active not recruiting
26 enrolled 10 charts
Head & Neck

Erythroplasia, Hyperplasia, Leukoplakia, Oral, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡